NTLA vs. BMY
Compare and contrast key facts about Intellia Therapeutics, Inc. (NTLA) and Bristol-Myers Squibb Company (BMY).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: NTLA or BMY.
Correlation
The correlation between NTLA and BMY is 0.21, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
NTLA vs. BMY - Performance Comparison
Key characteristics
NTLA:
-0.79
BMY:
0.75
NTLA:
-1.05
BMY:
1.37
NTLA:
0.88
BMY:
1.17
NTLA:
-0.53
BMY:
0.45
NTLA:
-1.57
BMY:
1.86
NTLA:
31.46%
BMY:
11.51%
NTLA:
62.06%
BMY:
28.43%
NTLA:
-92.58%
BMY:
-70.62%
NTLA:
-91.67%
BMY:
-22.06%
Fundamentals
NTLA:
$1.39B
BMY:
$119.34B
NTLA:
-$5.45
BMY:
-$3.61
NTLA:
-0.10
BMY:
2.01
NTLA:
$43.09M
BMY:
$47.44B
NTLA:
$35.51M
BMY:
$33.40B
NTLA:
-$527.52M
BMY:
$5.06B
Returns By Period
In the year-to-date period, NTLA achieves a -51.72% return, which is significantly lower than BMY's 19.00% return.
NTLA
-51.72%
-12.01%
-38.02%
-48.08%
-2.63%
N/A
BMY
19.00%
7.35%
38.69%
19.51%
1.64%
3.06%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
NTLA vs. BMY - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Intellia Therapeutics, Inc. (NTLA) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
NTLA vs. BMY - Dividend Comparison
NTLA has not paid dividends to shareholders, while BMY's dividend yield for the trailing twelve months is around 4.13%.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NTLA Intellia Therapeutics, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
BMY Bristol-Myers Squibb Company | 4.13% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% | 2.46% | 3.31% |
Drawdowns
NTLA vs. BMY - Drawdown Comparison
The maximum NTLA drawdown since its inception was -92.58%, which is greater than BMY's maximum drawdown of -70.62%. Use the drawdown chart below to compare losses from any high point for NTLA and BMY. For additional features, visit the drawdowns tool.
Volatility
NTLA vs. BMY - Volatility Comparison
Intellia Therapeutics, Inc. (NTLA) has a higher volatility of 21.02% compared to Bristol-Myers Squibb Company (BMY) at 11.94%. This indicates that NTLA's price experiences larger fluctuations and is considered to be riskier than BMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
NTLA vs. BMY - Financials Comparison
This section allows you to compare key financial metrics between Intellia Therapeutics, Inc. and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities